Boehringer Ingelheim at F2
As of the edition of 20 October 2026, Boehringer Ingelheim is on route B at F2 (prothrombin), position 19 of 2,016 on that route, with a score of 0.756.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.756
Biology proven in humans0.85
How much the company cares0.75
Room, and a reason to act now0.67
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Few other companies active at the target+0.128
Trials at the target more often meet than miss their main endpoint+0.057
The company’s own follow-on drug+0.044
Active at the target or its disease area recently+0.029
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 13 August 2008.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 17 March 2008.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 17 March 2008.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Dabigatran etexilate | Marketed | Phase 4 | 131 | Patent ends: 7 September 2025 |
| Dabigatran | Marketed | Phase 4 | 99 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT01153698 | Dabigatran | Terminated | 2010 to 2011 | 167 | No results posted | |
| The registry records: “This trial was prematurely discontinued due to low enrolment.” | ||||||
| NCT02171546 | Dabigatran etexilate | Phase 1 | Terminated | 2007 | 42 | No results posted |
| NCT00157248 | Dabigatran etexilate | Phase 2 | Terminated | 2003 | 361 | No results posted |
| NCT04532528 | Dabigatran | Completed | 2020 to 2023 | 897 | Main endpoint missed | |
| NCT03258645 | Dabigatran | Completed | 2018 to 2019 | 1,489 | Result could not be read | |
| NCT03254134 | Dabigatran | Completed | 2017 to 2017 | 22,490 | Result could not be read | |
| NCT03254147 | Dabigatran | Completed | 2017 to 2017 | 53,969 | No results posted | |
| NCT03026556 | Dabigatran | Completed | 2016 to 2017 | 42,534 | Mixed result | |
| NCT02631057 | Dabigatran | Completed | 2016 to 2016 | 4,313 | Main endpoint met | |
| NCT02849509 | Dabigatran | Completed | 2016 to 2017 | 1,313 | Mixed result | |
| NCT02223260 | Dabigatran | Phase 2 | Completed | 2014 to 2016 | 8 | No results posted |
| NCT02149303 | Dabigatran | Completed | 2014 to 2015 | 191 | No results posted | |